- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03816956
Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301 (AR-301-002)
A Randomized Double-blind Placebo-controlled Multicenter Phase 3 Study of Efficacy and Safety of AR-301 as Adjunct Therapy to Antibiotics in the Treatment of Ventilator-Associated Pneumonia (VAP) Caused by S. Aureus
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is an international, multicenter, prospective, randomized, double blind, placebo controlled, parallel design protocol in patients with Ventilator-Associated Pneumonia (VAP) caused by S. aureus.
Patients with a documented diagnosis of pneumonia due to S. aureus, and require ICU care, who have been intubated (or have a tracheostomy tube in place) and mechanically ventilated for at least 48 hours are eligible for screening.
In total, approximately 240 subjects will be randomized 1-1 to be treated with placebo plus standard of care (SOC) or AR-301 (20 mg/kg) plus SOC in this Phase 3 study.
Study subjects will receive a single dose at Day 0 in addition to SOC antibiotic treatment, and then enter a safety, efficacy and PK study period for a total study duration of 28 days. The selection of SOC antibiotics is made in accordance with local best practices at the discretion of the investigator.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Lynne M Deans, MT
- Phone Number: 9252003089 925-200-3089
- Email: deansl@aridispharma.com
Study Locations
-
-
-
Gomel, Belarus, 246029
- BLR-04
-
Grodno, Belarus, 230017
- BLR-06
-
Minsk, Belarus, 223041
- BLR-01
-
-
-
-
-
Lodelinsart, Belgium, 6042
- BEL-01
-
Ottignies, Belgium, 1340
- BEL-05
-
-
-
-
-
Curitiba, Brazil, 80810-050
- BRA-08
-
Curitiba, Brazil, 82050-350
- BRA-04
-
-
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510180
- CHN-09
-
-
-
-
-
Tallinn, Estonia, 13419
- EST-01
-
-
-
-
-
Brive-la-Gaillarde, France, 19312
- FRA-18
-
Bron, France, 69677
- FRA-10
-
La Roche-sur-Yon, France, 85925
- FRA-05
-
Limoges, France, 87042
- FRA-04
-
Nantes, France, 44093
- FRA-01
-
Orléans, France, 45067
- FRA-16
-
Rennes, France, 35033
- FRA-11
-
Trevenans, France, 90400
- FRA-13
-
-
Cedex
-
Strasbourg, Cedex, France, 67091
- FRA-02
-
-
-
-
-
Gori, Georgia, 1400
- GEO-06
-
Kutaisi, Georgia, 4600
- GEO-01
-
Kutaisi, Georgia, 4600
- GEO-03
-
Kutaisi, Georgia, 4600
- GEO-04
-
Kutaisi, Georgia, 4600
- GEO-10
-
Tbilisi, Georgia, 0141
- GEO-02
-
Tbilisi, Georgia, 0159
- GEO-09
-
Tbilisi, Georgia, 0160
- GEO-07
-
-
-
-
-
Haifa, Israel, 31096
- ISR-04
-
Ramat Gan, Israel, 5262100
- ISR-01
-
-
-
-
-
Riga, Latvia, LV-1006
- LVA-02
-
-
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44280
- MEX-07
-
-
-
-
-
Arkhangelsk, Russian Federation, 163002
- RUS-18
-
Chelyabinsk, Russian Federation, 454000
- RUS-11
-
Krasnoyarsk, Russian Federation, 660022
- RUS-01
-
Novosibirsk, Russian Federation, 630051
- RUS-04
-
Saint Petersburg, Russian Federation, 192242
- RUS-02
-
Smolensk, Russian Federation, 214018
- RUS-10
-
Zhukovskiy, Russian Federation, 140180
- RUS-16
-
-
-
-
-
Johannesburg, South Africa, 2193
- ZAF-09
-
-
-
-
-
Madrid, Spain, 28040
- ESP-01
-
-
-
-
-
Istanbul, Turkey, 34214
- TUR-06
-
Trabzon, Turkey, 61080
- TUR-01
-
-
-
-
-
Chernivtsi, Ukraine, 58000
- UKR-05
-
Ivano-Frankivsk, Ukraine, 76008
- UKR-03
-
Kharkiv, Ukraine, 61103
- UKR-02
-
Kharkiv, Ukraine, 61103
- UKR-09
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written Informed Consent given by the patient or, if not possible, by a legally acceptable representative and/or an independent physician as authorized by the competent ethics committee (EC) or independent review board (IRB) and local regulations.
- To be at least 18 years of age. Taiwan only: To be at least 20 years of age. South Korea only: To be at least 19 years of age.
- Treated in an ICU at the time of enrollment.
- Endotracheal tube in place (tracheostomy is allowed).
- The patient is mechanically ventilated for at least 48 hours.
Diagnosis of pneumonia based on the following criteria (a, b, and c, all must be met):
- One definitive chest X-ray diagnostic of pneumonia within 48 hours,
- Hypoxemia based on PaO2/FiO2.
- At least one of the following signs:
i. Documented fever (e.g., body temperature greater than or equal to 38º Celsius).
ii. Hypothermia (e.g., core body temperature less than or equal to 35º Celsius).
iii. Total peripheral white blood cell (WBC) count greater than or equal to 10,000 cells/µL (or mm3).
iv. Leukopenia with total WBC less than or equal to 4,500 cells/µL (mm3). v. Greater than 15 percent immature neutrophils (bands) noted on peripheral blood smear.
- Documented pulmonary infection with Staphylococcus aureus obtained by bronchoalveolar lavage (BAL), mini-BAL, protected endotracheal aspiration/aspirate (ETA) (collectively 'airway specimen').
Exclusion Criteria
- The subject is unlikely to survive for the study duration despite delivery of adequate antibiotics and supportive care for treatment of S. aureus pneumonia.
- Effective antibacterial drug therapy for the index pneumonia administered continuously for 48 hours or more prior to initiation of study treatment. Effective antibiotics would include those typically used to treat S. aureus.
- Plasmapheresis (ongoing or planned), extracorporeal membrane oxygenation (ECMO) or any procedure that would remove/filter out the monoclonal antibody/study drug.
- Immunocompromised patients.
- Known hereditary complement deficiency.
- Liver dysfunction with a Child Pugh C score > 9 (Child Pugh score of A or B are acceptable at discretion of the Principal Investigator [PI]).
- Pulmonary disease that precludes evaluation of a therapeutic response (such as lung cancer resulting in bronchial obstruction or on the same side as the pneumonia, active tuberculosis, cystic fibrosis, granulomatous disease, fungal pulmonary infection, lung abscess, pleural empyema or post obstructive pneumonia).
- Patient has received intravenous (IV) immunoglobulin therapy within 3 months prior to the Screening Visit.
- Any woman of child-bearing potential (WOCBP) who does not have a negative pregnancy test result at Screening using SERUM or URINE testing based on Beta-subunit human chorionic gonadotropin (HCG) standard tests and methods from the local laboratory.
- Any sexually active subject who is unwilling to use acceptable methods of contraception for 120 days after dosing.
- Known lack of treatment compliance from prior studies or ongoing medical care based on medical records and PI's judgment and/or the capacity of the patient to comply with all study requirements.
- Any medical, psychological, cognitive, social or legal conditions that would interfere in the ability to give an Informed Consent OR the absence of a legally valid representative of the patient or independent physician allowed and able to give consent on his/her behalf.
- Participation as a subject in another interventional study within 30 days prior to the first dose of study treatment, or planned participation in such a study during the study or within 30 days of its completion by the patient.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study treatment
Investigational/ Interventional Product group: AR-301 (tosatoxumab) 20 mg/kg administered once intravenously on the day of randomization.
|
AR-301 (tosatoxumab) 20 mg/kg administered once intravenously the day of enrolment.
Other Names:
|
Placebo Comparator: Placebo treatment
Control group: Placebo administered intravenously on the day of randomization.
|
Placebo comparator
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
A comparison of Clinical Cure Rates of standard of care (SOC) alone and SOC with AR-301
Time Frame: 21 days
|
Clinical cure rates of standard of care (SOC) alone and (SOC) with AR-301 at Day 21 as measured by all-cause mortality, need for mechanical ventilation and signs and symptoms of pneumonia.
|
21 days
|
Safety of AR-301 by treatment-emergent adverse events assessed by changes between treatment and placebo as assessed by the Principal Investigator
Time Frame: 21 Days
|
Safety of AR-301 of treatment-emergent adverse events as assessed by changes assessed by the PI between treatment and placebo
|
21 Days
|
Tolerability of AR-301 measured by the number of participants with treatment-emergent adverse events classified using CTCAE v 5.0
Time Frame: 21 Days
|
Tolerability of AR-301 will be measured and evaluated by the severity of treatment-emergent adverse events using the CTCAE v 5.0.
|
21 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The difference in clinical cure rates between Standard of Care alone or with AR301 as time to clinical cure at Day 7, 14 and 28
Time Frame: Day 7, 14, and 28
|
Difference in Clinical Cure rates between SOC alone or with AR-301 defined by time to clinical cure (number of days) using the same criteria as for the primary efficacy objective at Day 21.
|
Day 7, 14, and 28
|
The difference in mortality between Standard of Care alone or with AR-301 at Days 7,14,28
Time Frame: Day 7, 14, and 28
|
Difference in mortality defined as cause of death (all-cause mortality and pneumonia-related mortality)between SOC alone or with AR-301 at Days 7,14, and 28
|
Day 7, 14, and 28
|
The difference in PaO2/FiO2 between Standard of Care alone or with AR-301 at Days 7,14,28
Time Frame: Day 7, 14, and 28
|
Difference in respiratory function between SOC alone or with AR-301 at Days 7,14, and 28 as changes in PaO2/FiO2 ratio (e.g. by arterial blood gases), if available and whenever possible OR changes in non-invasive measures of oxygenation (e.g. by pulse oximetry)
|
Day 7, 14, and 28
|
The difference in time on supplemental oxygen assessment between Standard of Care alone or with AR-301 at Days 7,14,28
Time Frame: Day 7, 14, and 28
|
Difference in respiratory function between SOC alone or with AR-301 at Days 7,14, and 28 as time on supplemental oxygen
|
Day 7, 14, and 28
|
Changes in baseline in SOFA score between Standard of Care alone or with AR301 at Days 7,14,28
Time Frame: Day 7, 14, and 28
|
Difference in Clinical Cure rates between SOC alone or with AR-301 at Days 7,14, and 28 in the following clinical outcomes: Changes from Baseline in sequential organ failure assessment (SOFA) score using the following scale: Maximum SOFA score 0-6, <10% Mortality, 7-9 15-20% mortality, 10-12 40-50% mortality, 13-14 50-60% mortality, 15 >80% mortality, 15-24 >90% mortality. Lower numbers are considered to be better outcome of mortality and higher scores worse outcome of mortality. |
Day 7, 14, and 28
|
Duration of intubation with ventilation
Time Frame: 28 days
|
Number of days with intubation with ventilation
|
28 days
|
Duration mechanical ventilation if tracheostomy in place
Time Frame: 28 days
|
Number of days of intubation with mechanical ventilation if tracheostomy in place
|
28 days
|
Duration of stay in ICU
Time Frame: 28 days
|
Number of days of stay in ICU
|
28 days
|
Duration hospitalization
Time Frame: 28 days
|
Number of days of hospitalization
|
28 days
|
Duration antibiotic use.
Time Frame: 28 days
|
Number of days on antibiotics
|
28 days
|
Pharmacokinetic Analysis - (Cmax)
Time Frame: 28 days
|
Pharmacokinetic analysis measuring Maximum Serum Concentration (Cmax)
|
28 days
|
Pharmacokinetic Analysis - (AUC)
Time Frame: 28 Days
|
Pharmacokinetic analysis measuring Area Under the Curve (AUC)
|
28 Days
|
Pharmacokinetic Analysis - (T1/2)
Time Frame: 28 Days
|
Pharmacokinetic analysis measuring time for half of the initial dose of study drug to be eliminated from the body (T1/2)
|
28 Days
|
Pharmacokinetic Analysis - (Tmax)
Time Frame: 28 Days
|
Pharmacokinetic analysis measuring time at which Cmax is obtained (Tmax)
|
28 Days
|
Pharmacokinetic Analysis (Blood levels of AR-301)
Time Frame: 28 Days
|
Blood levels of AR-301 in the patient over time during the study period.
|
28 Days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Hasan S Jafri, MD, FAAP, Aridis Pharmaceuticals
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Disease Attributes
- Bacterial Infections and Mycoses
- Cross Infection
- Iatrogenic Disease
- Healthcare-Associated Pneumonia
- Infections
- Communicable Diseases
- Pneumonia
- Bacterial Infections
- Pneumonia, Ventilator-Associated
Other Study ID Numbers
- AR-301-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Staphylococcus Aureus
-
University Hospital TuebingenNot yet recruiting
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
University of SheffieldRajarata University, Sri LankaUnknown
-
NovaDigm Therapeutics, Inc.Uniformed Services University of the Health Sciences; Infectious Diseases Clinical...CompletedStaphylococcus AureusUnited States
-
Ohio State UniversityCompletedMethicillin-resistant Staphylococcus Aureus | Methicillin-Sensitive Staphylococcus Aureus InfectionUnited States
-
Todd C. Lee MD MPH FIDSANot yet recruitingStaphylococcus Aureus Bacteremia | Staphylococcus Aureus Endocarditis | Staphylococcus Aureus Septicemia | Staphylococcal SepsisCanada
-
Forest LaboratoriesCompletedStaphylococcus Aureus Bacteremia | Methicillin-resistant Staphylococcus Aureus (MRSA) BacteremiaUnited States
-
Armata Pharmaceuticals, Inc.United States Department of DefenseRecruitingBacteremia | Staphylococcus Aureus | Staphylococcus Aureus Bacteremia | Bacteremia Due to Staphylococcus Aureus | Bacteremia StaphUnited States, Australia
-
Intron Biotechnology, Inc.CompletedHealthy Volunteers | Anti-Bacterial Agents | Methicillin-Resistant Staphylococcus Aureus | Methicillin-Sensitive Staphylococcus Aureus InfectionKorea, Republic of
-
Menzies School of Health ResearchThe University of Queensland; Australasian Society for Infectious Diseases; Singapore... and other collaboratorsTerminatedMethicillin-Resistant Staphylococcus AureusAustralia, New Zealand, Israel, Singapore
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States